JP2016518140A - Ｉ型インターフェロンの環状ジヌクレオチド誘導法 - Google Patents

Ｉ型インターフェロンの環状ジヌクレオチド誘導法 Download PDF

Info

Publication number
JP2016518140A
JP2016518140A JP2016512084A JP2016512084A JP2016518140A JP 2016518140 A JP2016518140 A JP 2016518140A JP 2016512084 A JP2016512084 A JP 2016512084A JP 2016512084 A JP2016512084 A JP 2016512084A JP 2016518140 A JP2016518140 A JP 2016518140A
Authority
JP
Japan
Prior art keywords
cyclic dinucleotide
cyclic
cells
sting
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512084A
Other languages
English (en)
Japanese (ja)
Inventor
ラッセル イー． ヴァンス
ラッセル イー． ヴァンス
ミング シー． ハモンド
ミング シー． ハモンド
ダーラ バーデット
ダーラ バーデット
エリー ジェイ． ダイナー
エリー ジェイ． ダイナー
スティーブン シー． ウィルソン
スティーブン シー． ウィルソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2016518140A publication Critical patent/JP2016518140A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016512084A 2013-05-03 2014-05-02 Ｉ型インターフェロンの環状ジヌクレオチド誘導法 Pending JP2016518140A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819499P 2013-05-03 2013-05-03
US61/819,499 2013-05-03
PCT/US2014/036685 WO2014179760A1 (en) 2013-05-03 2014-05-02 Cyclic di-nucleotide induction of type i interferon

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018237955A Division JP2019068829A (ja) 2013-05-03 2018-12-20 Ｉ型インターフェロンの環状ジヌクレオチド誘導法

Publications (1)

Publication Number Publication Date
JP2016518140A true JP2016518140A (ja) 2016-06-23

Family

ID=51841746

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016512084A Pending JP2016518140A (ja) 2013-05-03 2014-05-02 Ｉ型インターフェロンの環状ジヌクレオチド誘導法
JP2018237955A Pending JP2019068829A (ja) 2013-05-03 2018-12-20 Ｉ型インターフェロンの環状ジヌクレオチド誘導法
JP2021025792A Withdrawn JP2021074025A (ja) 2013-05-03 2021-02-22 Ｉ型インターフェロンの環状ジヌクレオチド誘導法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018237955A Pending JP2019068829A (ja) 2013-05-03 2018-12-20 Ｉ型インターフェロンの環状ジヌクレオチド誘導法
JP2021025792A Withdrawn JP2021074025A (ja) 2013-05-03 2021-02-22 Ｉ型インターフェロンの環状ジヌクレオチド誘導法

Country Status (6)

Country Link
US (3) US20140329889A1 (OSRAM)
EP (1) EP2992000B1 (OSRAM)
JP (3) JP2016518140A (OSRAM)
CN (1) CN105377867B (OSRAM)
ES (1) ES2822584T3 (OSRAM)
WO (1) WO2014179760A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021520389A (ja) * 2018-04-06 2021-08-19 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ２’３’−環状ジヌクレオチド

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
BR112015013440B1 (pt) 2012-12-13 2020-12-08 Aduro Biotech, Inc composições compreendendo dinucleotídeos de purina cíclicos com estereoquímicas
WO2014099824A1 (en) 2012-12-19 2014-06-26 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
CA2908154C (en) 2013-04-29 2023-11-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
SI2996473T1 (sl) 2013-05-18 2019-12-31 Aduro Biotech, Inc. Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov"
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
EP3027227A4 (en) * 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
ES2692226T3 (es) 2014-06-04 2018-11-30 Glaxosmithkline Intellectual Property Development Limited Dinucleótidos cíclicos como moduladores de STING
US20170340658A1 (en) * 2014-12-16 2017-11-30 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
US10011630B2 (en) 2014-12-16 2018-07-03 Invivogen Cyclic dinucleotides for cytokine induction
US20180344758A1 (en) * 2014-12-17 2018-12-06 Lipogen Llc Method of Treating Cancer with cGAMP or cGAsMP
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
CN106692967A (zh) * 2015-08-12 2017-05-24 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP联合PD1的抗体（Nivolumab）在制备抗肿瘤药物中的应用
CA2995365C (en) 2015-08-13 2021-10-12 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US9809597B2 (en) 2015-08-20 2017-11-07 The Board Of Trustees Of The Leland Stanford Junior University Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
CN106540255A (zh) * 2015-09-18 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用
US10322177B2 (en) 2015-10-07 2019-06-18 Nant Holdings Ip, Llc Activation of immune-related signaling pathways in cells via optofection
AU2016343993A1 (en) 2015-10-28 2018-05-10 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
CN106539812B (zh) * 2015-11-18 2019-12-03 杭州星鳌生物科技有限公司 环二核苷酸cGAMP在抗结直肠癌肝转移中的应用
CN106539813B (zh) * 2015-11-30 2019-12-03 杭州星鳌生物科技有限公司 干扰素刺激基因(sting)激活剂在抗炎症中的应用
CR20180286A (es) 2015-12-03 2018-07-16 Glaxosmithkline Ip Dev Ltd Dinucleotidos de purina cíclicos como moduladores de sting
CN106540260A (zh) * 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用
CN106539814A (zh) * 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白（sting）激动剂在抗类风湿性关节炎等疾病中的应用
WO2017106740A1 (en) * 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
CN106539811B (zh) * 2016-01-16 2019-12-20 杭州星鳌生物科技有限公司 环二核苷酸cGAMP在防治抗肿瘤化药诱发的并发症或降低化疗药诱导的毒副作用中的应用
CN106539815B (zh) * 2016-01-21 2019-12-03 杭州星鳌生物科技有限公司 环二核苷酸在防治多发性硬化症中的应用
MX390014B (es) * 2016-03-18 2025-03-20 Immune Sensor Llc Compuestos de dinucleótidos cíclicos y métodos de uso.
CN106539757A (zh) * 2016-03-20 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用
CN106540256A (zh) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
CN105969754A (zh) * 2016-04-29 2016-09-28 山东省农业科学院畜牧兽医研究所 改造的核苷酸环化酶及其应用
US10696985B1 (en) 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
CN106552265A (zh) * 2016-06-21 2017-04-05 聊城市奥润生物医药科技有限公司 Sting激动剂与ido1抑制剂联合用药在抗肿瘤中的应用
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
TWI689514B (zh) * 2016-07-06 2020-04-01 美商史貝羅威生物科學有限公司 化合物、組合物及用於治療疾病之方法
WO2018009652A1 (en) * 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
BR112019004042A2 (pt) 2016-08-30 2019-05-28 Dana-Farber Cancer Institute, Inc. composições de liberação de fármaco e usos das mesmas
EA037513B1 (ru) * 2016-09-17 2021-04-06 ИММЬЮН СЕНСОР, ЭлЭлСи Циклические динуклеотидные соединения и способы их применения
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
CR20190168A (es) 2016-10-04 2019-05-17 Merck Sharp & Dohme Compuestos de benzo[b]tiofeno como agonistas de sting
US11001605B2 (en) 2016-10-07 2021-05-11 Biolog Life Science Institute Gmbh & Co. Kg Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
BR112019007450A2 (pt) 2016-10-14 2020-07-07 Precision Biosciences, Inc. meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
BR112019012618A2 (pt) * 2016-12-22 2019-11-26 Mavupharma Inc inibidores de fosfodiesterase e métodos de tratamento microbiano
WO2018119325A1 (en) * 2016-12-22 2018-06-28 Mavupharma, Inc. Compositions and methods of enhancing or augmenting type i ifn production
US11492367B2 (en) * 2017-01-27 2022-11-08 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
JP2018131427A (ja) * 2017-02-17 2018-08-23 国立研究開発法人理化学研究所 免疫細胞の制御技術
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
CN106727331B (zh) * 2017-03-13 2022-02-01 杭州星鳌生物科技有限公司 免疫脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
CN106667914B (zh) * 2017-03-13 2022-02-01 杭州星鳌生物科技有限公司 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
CN110651036A (zh) 2017-03-20 2020-01-03 健诺西生物科学公司 治疗方法
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
SG11201908813QA (en) 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
IL269970B (en) 2017-04-14 2022-09-01 Tallac Therapeutics Inc Polynucleotides that modulate the immune system, their antibody binding, and methods of using them
WO2018208667A1 (en) 2017-05-12 2018-11-15 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
PL3678668T3 (pl) 2017-09-08 2024-06-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
CN107619438B (zh) * 2017-10-11 2021-12-03 广州云启科技有限公司 新型环二核苷酸受体及其激动剂或抑制剂筛选的方法和试剂盒
CN109694397B (zh) * 2017-10-23 2021-08-31 上海弘翊生物科技有限公司 环状二核苷酸化合物、其制备方法和应用
WO2019092660A1 (en) 2017-11-10 2019-05-16 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
EP3728282B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
EP3743103A4 (en) * 2018-01-26 2021-03-17 The Regents of The University of California INTRANASAL ADMINISTRATION OF CYCLIC DI-NUCLEOTIDE ADJUVED VACCINE FOR TUBERCULOSIS
WO2019161171A1 (en) * 2018-02-16 2019-08-22 Sperovie Biosciences, Inc. Nanoparticle formulations of sting agonists
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
CA3093849A1 (en) 2018-03-23 2019-09-26 Codiak Biosciences, Inc. Extracellular vesicles comprising sting-agonist
CA3097850A1 (en) * 2018-03-26 2019-10-03 University Of Miami Recombinant viral vector and uses thereof
WO2019185476A1 (en) 2018-03-27 2019-10-03 Boehringer Ingelheim International Gmbh Modified cyclic dinucleotide compounds
EP3774834A1 (en) 2018-03-27 2021-02-17 Boehringer Ingelheim International GmbH Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
CN111971277B (zh) 2018-04-03 2023-06-06 默沙东有限责任公司 作为sting激动剂的苯并噻吩及相关化合物
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CN108310378A (zh) * 2018-04-28 2018-07-24 杭州星鳌生物科技有限公司 一类新型免疫联体抗肿瘤创新药物的制备及其应用
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
EP3794010A4 (en) * 2018-05-17 2022-03-23 The Regents of The University of California Methods of modulating activity of a cyclic dinucleotide (cdn) with a cdn transporter-modulating agent
SG11202011434SA (en) 2018-06-01 2020-12-30 Eisai R&D Man Co Ltd Methods for the treatment of bladder cancer
AU2019294632A1 (en) * 2018-06-29 2021-02-04 Dana-Farber Cancer Institute, Inc. Structure of the human cGAS-DNA complex and uses thereof
WO2020014127A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
MX2020013322A (es) 2018-08-16 2021-02-22 Eisai R&D Man Co Ltd Sales de compuestos y cristales de los mismos.
EP3841112A1 (en) 2018-08-24 2021-06-30 Codiak BioSciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
KR102755652B1 (ko) 2018-09-21 2025-01-21 상하이 드 노보 파마테크 컴퍼니 리미티드 고리형 디뉴클레오티드 유사체, 이의 약학 조성물 및 용도
AU2019373241A1 (en) 2018-10-29 2021-06-10 Genocea Biosciences, Inc. Treatment methods
WO2020092633A1 (en) 2018-10-30 2020-05-07 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
CN113227089B (zh) 2018-10-31 2024-07-05 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
WO2020179714A1 (ja) * 2019-03-01 2020-09-10 ヤマサ醤油株式会社 ３'，３'－ｃＧＡＭＰの実践的酵素合成法
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
PH12021552223A1 (en) 2019-03-21 2022-05-30 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
MX2021011242A (es) 2019-03-21 2022-01-19 Codiak Biosciences Inc Conjugados de vesícula extracelular y usos de estos.
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3966222A4 (en) 2019-05-09 2023-10-04 Aligos Therapeutics, Inc. MODIFIED CYCLIC DI-NUCLEOSIDE COMPOUNDS AS STING MODULATORS
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
WO2021003445A1 (en) 2019-07-03 2021-01-07 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP3785719A1 (en) * 2019-08-28 2021-03-03 Helmholtz-Zentrum für Infektionsforschung GmbH New use of cyclic dinucleotides
WO2021062060A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour
WO2021062058A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
KR20220092654A (ko) 2019-09-25 2022-07-01 코디악 바이오사이언시즈, 인크. 세포외 소포 조성물
EP4034276A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
JP2022551121A (ja) * 2019-10-07 2022-12-07 ザ ジェネラル ホスピタル コーポレイション 肺サーファクタント生体模倣ナノ粒子に関する組成物および方法
ES3022990T3 (en) 2019-12-06 2025-05-29 Prec Biosciences Inc Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
AU2021236763A1 (en) 2020-03-20 2022-10-06 Lonza Sales Ag Extracellular vesicles for therapy
TWI845826B (zh) 2020-03-20 2024-06-21 美商基利科學股份有限公司 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
MX2023001507A (es) 2020-08-07 2023-03-06 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico.
US12036319B2 (en) 2020-09-08 2024-07-16 The Board Of Regents Of The University Of Texas System Polyvalent sting activating compositions and uses thereof
WO2022066898A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
EP4291222A4 (en) * 2021-02-12 2025-01-08 The Regents of University of California METHODS OF INCIDENTAL INTERFERON RESPONSE BY REGULATION OF MORC3
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
US12208150B2 (en) * 2021-05-20 2025-01-28 Shielded, Beauty, LLC Antimicrobial skincare composition
CN113265435A (zh) * 2021-06-16 2021-08-17 中国农业科学院兰州兽医研究所 一种细菌第二信使分子环二核苷酸的制备方法
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
EP4569129A1 (en) * 2022-08-10 2025-06-18 Aldevron, LLC Methods for producing cyclic dinucleotides
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007529531A (ja) * 2004-03-15 2007-10-25 ケイ．アール． カラオリス，デイヴィッド 免疫、炎症または神経保護応答のための方法
US20120164107A1 (en) * 2010-12-15 2012-06-28 Portnoy Daniel A Cyclic di-amp induction of type i interferon
WO2014093936A1 (en) * 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
WO2014099824A1 (en) * 2012-12-19 2014-06-26 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
WO2014179335A1 (en) * 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
JPH06505186A (ja) 1991-02-11 1994-06-16 オマーヤ，アユブ　ケー． 脊髄液駆動式人工器官
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US6464973B1 (en) 1998-02-02 2002-10-15 Johns Hopkins University, School Of Medicine Universal GM-CSF expressing bystander human K562 cell line
ES2198970T3 (es) 1998-09-16 2004-02-01 Alza Corporation Inhibidores de topoisomerasa atrapados en liposomas.
BR0008227A (pt) * 1999-02-15 2001-10-30 Nippon Shinyaku Co Ltd Polinucleotìdeos de cadeia curta e método para apreparação dos mesmos
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
ATE324888T1 (de) 1999-06-14 2006-06-15 Cancer Rec Tech Ltd Krebstherapie
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
JP2003507438A (ja) 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2002024739A2 (en) 2000-09-21 2002-03-28 The Regents Of The University Of California Spas-1 cancer antigen
US7279883B2 (en) 2001-01-23 2007-10-09 Lydia L. Sohn Particle analyzer and methods for use thereof
EP1401473B1 (en) 2001-02-16 2009-07-29 Cellgate Inc. Transporters comprising spaced arginine moieties
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CA2533873A1 (en) * 2003-07-28 2005-04-07 David K.R. Karaolis Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
EP1682173A4 (en) 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINE ON LISTERIA BASE
CA2542804A1 (en) 2003-10-24 2005-05-06 Alza Corporation Preparation of lipid particles
US7592326B2 (en) * 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
ES2967961T3 (es) 2004-05-03 2024-05-06 Ipsen Biopharm Ltd Liposomas útiles en la administración de fármacos
US8187571B1 (en) 2004-10-05 2012-05-29 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
CA2607579A1 (en) 2005-05-06 2006-11-23 The Regents Of The University Of California Microfluidic system for identifying or sizing individual particles passing through a channel
US20070059683A1 (en) 2005-09-15 2007-03-15 Tom Barber Veterinary diagnostic system
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
EP3000480A1 (en) 2005-12-01 2016-03-30 ProNAi Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
AU2007244826B2 (en) 2006-04-25 2013-04-11 The Regents Of The University Of California Administration of growth factors for the treatment of CNS disorders
WO2008030887A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
DK2205268T3 (da) * 2007-06-15 2012-11-26 Hi Stem Heidelberg Inst For Stem Cell Technology And Ex Medicine Gemeinnuetzige Gmbh Sekventielt behandlingsregime med interferon alfa til behandling af cancer
EP2257250A2 (en) 2008-01-29 2010-12-08 Gilbert H. Kliman Drug delivery devices, kits and methods therefor
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
WO2010017248A2 (en) 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
CN102333538B (zh) 2008-12-09 2014-01-15 科勒制药集团有限公司 免疫刺激性寡核苷酸
WO2010104883A1 (en) 2009-03-09 2010-09-16 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
US8414630B2 (en) 2009-03-10 2013-04-09 Marc Evan Richelsoph Active bone screw
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
WO2011003025A1 (en) 2009-07-01 2011-01-06 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
US8771933B2 (en) 2009-10-06 2014-07-08 Massachusetts Institute Of Technology Continuous-flow deformability-based cell separation
US20110287948A1 (en) 2010-03-22 2011-11-24 Massachusetts Institute Of Technology Measurement of material properties and related methods and compositions based on cytoadherence
JP6042802B2 (ja) 2010-04-27 2016-12-14 ザ・ジョンズ・ホプキンス・ユニバーシティ 新生物（腫瘍）を治療するための免疫原性組成物及び方法。
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
SMT201800444T1 (it) 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
US9880084B2 (en) 2011-04-15 2018-01-30 The University Of British Columbia Apparatus for separation of particles
CA2847837A1 (en) * 2011-09-05 2013-03-14 Hanmi Science Co., Ltd. A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate
WO2013086331A1 (en) 2011-12-07 2013-06-13 President And Fellows Of Harvard College High efficiency di-nucleotide cyclase
CA2907616A1 (en) 2012-04-30 2013-11-07 Glen N. Barber Modulating immune responses
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
US9090646B2 (en) * 2012-12-05 2015-07-28 Rutgers, The State University Of New Jersey Biotinylated compounds
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US9549944B2 (en) * 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
SI2996473T1 (sl) 2013-05-18 2019-12-31 Aduro Biotech, Inc. Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov"
EP3027227A4 (en) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
AU2014340269B2 (en) 2013-10-21 2018-06-21 Drexel University Use of STING agonists to treat chronic hepatitis B virus infection
WO2015077354A1 (en) 2013-11-19 2015-05-28 The University Of Chicago Use of sting agonist as cancer treatment
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
WO2015108595A1 (en) 2014-01-15 2015-07-23 Nikolai Khodarev Anti-tumor therapy
ES2692226T3 (es) 2014-06-04 2018-11-30 Glaxosmithkline Intellectual Property Development Limited Dinucleótidos cíclicos como moduladores de STING
CA2995365C (en) 2015-08-13 2021-10-12 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007529531A (ja) * 2004-03-15 2007-10-25 ケイ．アール． カラオリス，デイヴィッド 免疫、炎症または神経保護応答のための方法
US20120164107A1 (en) * 2010-12-15 2012-06-28 Portnoy Daniel A Cyclic di-amp induction of type i interferon
WO2014093936A1 (en) * 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
WO2014099824A1 (en) * 2012-12-19 2014-06-26 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
WO2014179335A1 (en) * 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DINER E. ET AL., CELL REPORTS, vol. 3(2013 May 30), JPN6018023148, pages 1355 - 1361, ISSN: 0003820905 *
ERTEM G. ET AL., NATURE, vol. vol.379(1996), JPN6018023145, pages 238 - 240, ISSN: 0003820902 *
GAO P. ET AL., CELL, vol. 153(Epub 2013 May 3), JPN6018023147, pages 1094 - 1107, ISSN: 0003820904 *
LIBANOVA R. ET AL., MICROBIOAL BIOTECHNOLOGY, vol. 5(2)(2012), JPN6018023144, pages 168 - 176, ISSN: 0003820901 *
SAWAI H. ET AL., CHEM. PARM. BULL., vol. 29(8)(1981), JPN6018023146, pages 2237 - 2245, ISSN: 0003820903 *
SUN L. ET AL., SCIENCE, vol. vol.339(2013 Feb), JPN6018023143, pages 786 - 791, ISSN: 0004033865 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021520389A (ja) * 2018-04-06 2021-08-19 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ２’３’−環状ジヌクレオチド
JP7326321B2 (ja) 2018-04-06 2023-08-15 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ２’３’－環状ジヌクレオチド

Also Published As

Publication number Publication date
ES2822584T3 (es) 2021-05-04
WO2014179760A1 (en) 2014-11-06
EP2992000B1 (en) 2020-07-08
EP2992000A4 (en) 2017-01-04
US20190292216A1 (en) 2019-09-26
CN105377867B (zh) 2019-11-12
JP2021074025A (ja) 2021-05-20
CN105377867A (zh) 2016-03-02
US11873319B2 (en) 2024-01-16
US20140329889A1 (en) 2014-11-06
US20220081464A1 (en) 2022-03-17
EP2992000A1 (en) 2016-03-09
JP2019068829A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
US11873319B2 (en) Cyclic di-nucleotide induction of type I interferon
AU2023201482B2 (en) Cytokine conjugates for the treatment of autoimmune diseases
US10155014B2 (en) Cyclic di-AMP induction of type I interferon
US20220273767A1 (en) Interleukin 10 Conjugates and Uses Thereof
EP3083962B1 (en) Double-stranded polyc:poly(g/i) rna for immunostimulation and cancer treatment
WO2023284742A1 (en) Cells modified by conjugated n-terminal glycine and uses thereof
US20210275547A1 (en) Methods of Modulating Activity of a Cyclic Dinucleotide (CDN) with a CDN Transporter-Modulating Agent
WO2021141862A1 (en) Methods of modulating sting pathway activation
RU2829811C1 (ru) Конъюгаты интерлейкина 10 и варианты их применения
RU2787201C2 (ru) Конъюгаты цитокинов для лечения аутоиммунных заболеваний

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190515